Search
LivaNova PLC
LIVNAdd to Watchlist
82.230USD
-0.830-1.00%
Close 06/30, 16:00（ET）Quotes delayed by 15 min
4.51BMarket Cap
41.59P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-1.00%
5 Days
+4.51%
1 Month
+11.42%
6 Months
+32.03%
Year to Date
+33.64%
1 Year
+82.65%
Key Figures
82.770Open
82.915High
664.29KVolume
41.59P/E TTM
17.47P/E Dynamic
--Dividend TTM
1.21%Turnover Ratio
83.060Prev. Close
80.740Low
42.24MTurnover
71.39P/E Static
3.73P/B
0.00%Div Yield TTM
4.22%ROA
75.81552wk High
0.65Volume Ratio
63.23MNet Profit
54.90MShares
1.9772EPS TTM
0.87Beta
9.54%ROE
41.01552wk Low
2.62%Amplitude
67.29%Gross Margin
4.51BMarket Cap
6.49Reward/Risk
1.93%Risk Rate
TradingKey Stock Score of LivaNova PLC
Currency: USD Updated: 2026-06-30Key Insights
LivaNova PLC's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 26 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 81.54.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
LivaNova PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
LivaNova PLC Highlights
StrengthsRisks
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 20.33% year-on-year.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Overvalued
The company’s latest PE is 41.59, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 60.49M shares, decreasing 15.69% quarter-over-quarter.
Held by HOTCHKIS & WILEY
Star Investor HOTCHKIS & WILEY holds 478.62K shares of this stock.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
81.544
Target Price
-1.83%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
LivaNova PLC News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
LivaNova PLC Info
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
Ticker SymbolLIVN
CompanyLivaNova PLC
CEOMakatsaria (Vladimir A)
Websitehttps://www.livanova.com/
Related Instruments
-1.10%
-1.12%
-2.20%
-2.04%
-1.28%
-0.15%
-4.84%
-3.35%
-0.64%
-0.36%
-1.11%
-1.86%
+0.49%
-0.86%
+2.15%
-1.77%
-2.57%
-0.32%
-0.03%
-0.43%Popular Instruments
FAQs
What is the current price of LivaNova PLC (LIVN)?
The current price of LivaNova PLC (LIVN) is 82.23.
What is the symbol of LivaNova PLC?
The ticker symbol of LivaNova PLC is LIVN.
What is the 52-week high of LivaNova PLC?
The 52-week high of LivaNova PLC is 75.81.
What is the 52-week low of LivaNova PLC?
The 52-week low of LivaNova PLC is 41.02.
What is the market capitalization of LivaNova PLC?
The market capitalization of LivaNova PLC is 4.51B.
Is LivaNova PLC (LIVN) currently rated as Buy, Hold, or Sell?
According to analysts, LivaNova PLC (LIVN) has an overall rating of Buy, with a price target of 81.54.
What is the Earnings Per Share (EPS TTM) of LivaNova PLC (LIVN)?
The Earnings Per Share (EPS TTM) of LivaNova PLC (LIVN) is -4.45.
